[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100575254":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":31,"responsibleParty":51,"collaborators":20,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":20,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":20,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Xijing Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"before-after study in the same patient","EXPERIMENTAL","This is a prospective, open-label, single-center clinical study for renal cell carcinoma.\n\nSixty patients clinically suspected of having renal cell carcinoma and undergoing 68Ga-PSMA PET scans were included.\n\nQualified subjects underwent 68Ga-NOTA-RCCB6 PET scans within 7 days after completing the 68Ga-PSMA PET scan. Patient medical history was collected and laboratory tests were performed before the examination, and a biopsy or surgery was performed to obtain pathological results within 1 month after the examination, followed by a 6-month follow-up. The pathological results were used as the diagnostic gold standard.",[13],"Diagnostic Test: 68Ga-NOTA-RCCB6 PET\u002FCT Scan",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","68Ga-NOTA-RCCB6 PET\u002FCT Scan","The imaging agent 68Ga-NOTA-RCCB6 used in this project is synthesized following the standards for radiopharmaceutical production, with reference to the Chinese Pharmacopoeia (quality standards for 18F-FDG). The pH value is between 5.0 and 8.0; the radiochemical purity is not less than 95%, and the bacterial endotoxin content in each milliliter of solution is less than 15EU; the radioactive concentration is not less than 37 MBq\u002FmL; the solvent residues comply with the regulations.\n\nSpecification: 185\\~1850 MBq\u002Fml Characteristics: Clear, colorless, no visible particles. Radioactive physical half-life: 68Ga is 68 minutes. Expiry: Calculated from the time of labeling, stable for 3 half-lives. Administration method: Intravenous injection. Dosage: 0.05-0.1mCi\u002Fkg, flush with 5 mL of saline after injection. The maximum mass dose of CD70 should not exceed 240ug, and the maximum volume of administration should not exceed 5 mL.",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Ying Guo","CONTACT","0086+15991459177","guoying01192022@163.com",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},"he rui Li","0086+17563734669","3099595564@qq.com",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Department ofNuclear Medicine,Xijing Hospital, Fourth Military Medical University, Xi'an, China","RECRUITING","Xi'an, China","Shaanxi","710000","China","CN",{"type":41,"coordinates":42},"Point",[43,44],108.92861,34.25833,{"lat":44,"lon":43},[47,48,49],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},{"name":50,"role":24,"phone":20,"phoneExt":20,"email":20},"Jing Wang, Chairman of CSNM",{"type":52,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100575254","a-study-evaluating-the-value-of-68ga-nota-rccb6-pet-imaging-for-targeting-cd70-in-the-clinical-staging-therapeutic-evaluation-and-restaging-of-renal-cell-carcinoma-and-comparing-it-with-68ga-psma-petct-imaging-100575254",false,"NCT06769893","A Study Evaluating the Value of 68Ga-NOTA-RCCB6 PET Imaging for Targeting CD70 in the Clinical Staging, Therapeutic Evaluation, and Restaging of Renal Cell Carcinoma, and Comparing It with 68Ga-PSMA PET\u002FCT Imaging","A Prospective, Open-label, Single-center Study of CD70-Specific PET\u002FCT Imaging for Non-invasive Diagnosis of Renal Cell Carcinoma","Inclusion Criteria:\n\n\\- The subject or legal guardian\u002Fcaregiver must voluntarily sign the informed consent form.\n\nAges 18 to 75 years old. Patients with suspected renal cell carcinoma based on conventional imaging studies, and who undergo 68Ga-PSMA PET\u002FCT scanning.\n\nPatients with suspicious lymph nodes or distant metastases detected by conventional imaging or 68Ga-PSMA PET\u002FCT.\n\nWilling and able to follow the study protocol.\n\nExclusion Criteria:\n\n\\- Patients who have received anti-tumor treatment prior to PET\u002FCT scan. Suffer from severe other neurological diseases, or gastrointestinal, cardiovascular, liver, kidney, blood system, respiratory system, immunodeficiency and other serious diseases.\n\nAlternative subjects have contraindications to PET\u002FCT scanning. Including but not limited to: those who cannot tolerate repeated intravenous injections; those who may be allergic to the drug and its components (including those with a history of severe allergies or allergic reactions, especially those with allergies to the tested drug); claustrophobia.\n\nIn the past year, diagnosed with other malignant tumors; alternative subjects have undergone major surgery in the past 3 months; received experimental drug or device treatment with unclear effects or safety within the past month, or have participated in other interventional clinical trials.\n\nPregnant or lactating women. Patients who are lost to follow-up. Other conditions that, in the researcher's assessment, may affect the study or make the subject unsuitable for participation in the study.","ALL","18 Years","75 Years",{"count":64,"type":65},60,"ESTIMATED","INTERVENTIONAL",[68],"NA","This is a prospective, open-label, single-center clinical study targeting renal cell carcinoma. Sixty patients with a high clinical suspicion of renal cell carcinoma were included. Qualified subjects will undergo 68Ga-NOTA-RCCB6 PET\u002FCT examination. The aim is to establish the optimal imaging protocol; evaluate the distribution characteristics and correlations of physiological and pathological positive uptake, and using pathological results as the gold standard, assess the diagnostic efficacy of 68Ga-NOTA-RCCB6 PET\u002FCT in renal cell carcinoma.",[71],"RCC, Renal Cell Cancer",[73,74,75,76,77],"Renal cell cancer","PSMA","The cluster of differentiation (CD70)","Kidney tumor","ImmunoPET","2025-01-07",{"date":80,"type":81},"2025-01-10","ACTUAL",{"date":83,"type":81},"2024-06-12",{"date":85,"type":65},"2025-11-07",{"name":5,"class":6},1]